Nuclear medicine infrastructure for theranostics — the hospital nuclear medicine departments, specialized theranostic treatment centers, and outpatient radiopharmaceutical administration facilities creating the healthcare delivery infrastructure for the growing theranostic treatment market, with the Radiopharmaceutical Theranostics Market reflecting healthcare infrastructure as a commercial market access determinant.

Nuclear medicine capacity constraints — the approximately fifteen hundred US hospitals with nuclear medicine departments but only a fraction with theranostic treatment capability (radiation safety infrastructure, trained personnel, patient isolation rooms) — creating the access constraint limiting Pluvicto and Lutathera treatment reach. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) estimating significant US nuclear medicine workforce shortage and infrastructure gap for expanded theranostic delivery.

AUTHORIZED USER physician requirement — the NRC (Nuclear Regulatory Commission) requirement for physician Authorized User (AU) designation for administering therapeutic radiopharmaceuticals — creating the credentialing barrier requiring nuclear medicine physicians or radiation oncologists to obtain specific AU certification. The AU training program requirements and the limited number of AU-credentialed physicians constraining theranostic treatment site development.

Dosimetry in theranostics — the patient-specific dosimetry calculation determining absorbed radiation dose to tumor and critical organs enabling personalized treatment planning — represents the specialized capability creating premium theranostic centers. The EJNMMI-recommended dosimetry approach for 177Lu therapy and the growing evidence that dosimetry-guided treatment improves outcomes creating the clinical standard for advanced theranostic programs.

Do you think the nuclear medicine infrastructure and physician AU credentialing challenges will be resolved within five years to enable widespread theranostic treatment access in community oncology settings, or will theranostics remain predominantly academic center treatments?

FAQ

What infrastructure is required to offer theranostic treatments? Theranostic treatment requirements: NRC (or Agreement State) license for possession and use of unsealed radioactive materials; Authorized User physician (nuclear medicine physician or radiation oncologist with specific training); hot lab for radiopharmaceutical receipt and dispensing; inpatient room or outpatient suite for administration; radiation monitoring equipment; radioactive waste management; patient education and monitoring program; radiation safety officer; dosimetry capability (advanced centers); PSMA-PET scanner for patient selection; combined nuclear medicine and oncology coordination; significant upfront investment: approximately $500,000-2 million for new program.

What is an Authorized User (AU) for therapeutic radiopharmaceuticals? NRC Authorized User: physician credentialed by NRC (or Agreement State) for administering therapeutic radiopharmaceuticals; requirements: medical school and residency training; specific training hours in radiation safety and use for each therapeutic application; documented supervised cases; written NRC license or hospital license amendment; AU types: 10 CFR 35.394 (high-dose rate brachytherapy), 10 CFR 35.390 (sealed source therapy), 10 CFR 35.392 (unsealed byproduct materials — relevant for 177Lu therapy); challenge: limited number of physicians with 35.392 certification for 177Lu; SNMMI providing education; growing demand creating physician training bottleneck for theranostic program development.

#RadiopharmaceuticalTheranostics #NuclearMedicine #TheranosticInfrastructure #AuthorizedUser #NRCnuclear #TheranosticAccess